Thursday, March 31, 2011

RXi Pharmaceuticals Invites Biotech Speculators

Times have never been tougher if you are a preclinical-stage biotechnology company with a high demand for cash to support operations. At least this must be the conclusion that RXi Pharmaceuticals drew after it struggled to attract investor interest in their self-delivering RNAi trigger technology, but a technology that has yet to enter the clinic. As a result, it announced today that it will acquire late-stage cancer immunotherapy company Apthera.

Biotech investment these days is largely placing bets on the next drug approval candidate. There is little patient money that allows public companies to see through their technology development which especially hits those platform companies hard which cannot find alternative sources of non-dilutive capital. Talk about RNAi Therapeutics.

Actually, I liked the way that RXi has recently developed their fairly differentiated rxRNAs. These should have utility for a number of localized RNAi approaches. But it seems that RXi’s raison d’etre has never been the science anyway. So as we say good-bye to short-time CEO Noah Beerman, I wish everybody more of the Happy Trading that RXII has become known for.

3 comments:

Anonymous said...

RXI is a joke.

Anonymous said...

RXI is the future

Anonymous said...

Why is it ALNY that is covered with law suits and not RXi?

These guys are dealmakers. What you see is not what you get.

Good things coming.

By Dirk Haussecker. All rights reserved.

Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.